In the context of our collaboration with various stakeholders in the T2EVOLVE project, we are happy to share that the T2EVOLVE-QUALITOP European patient survey on CAR T-cell therapy is now open !
This survey will help to understand patients’ experiences with CAR T-cell therapy, evaluate the impact of this treatment on quality of life and identify unmet needs. With this information we aim to improve quality of life in patients receiving CAR T-cell therapy and their carers by optimizing support and improving the CAR T-cell treatment journey.
All European adult patients (≥ 18 years) who received CAR T-cell therapy for a hematologic malignancy (no specific indication required) can participate by filling in a digital survey.
Now, we need you!
If you are a patient treated with CAR T-cell therapy for a hematologic malignancy in Europe we would like to invite you to share your experiences with us by participating in our survey!
If you are not a patient but you are in close contact with patients who receive CAR T-cell therapy (e.g. a patient association, hematologist, nurse or other healthcare professional) we would like to invite you to help us by sharing this survey with patients!
You can use the attached QR code or the following link to access the survey (password: t2evolve): https://t2evolve.fyi/patientsurvey
The survey is available in English, French, German, Spanish, Italian, Portuguese and Dutch.
The survey will be open until the 31st July 2023.